强生三抗新药首次启动 III 期临床

丁香园 Insight 数据库
Dec 03, 2025

当地时间 12 月 2 日,强生在 ClinicalTrials 官网登记了一项JNJ-79635322治疗复发或难治性多发性骨髓瘤(RRMM)患者的 III 期研究 Trilogy-4。来源:ClinicalTrials 官网Trilogy-4是一项 III 期随机研究,旨在比较 JNJ-79635322 和抗 BCMAxCD3 双特异性抗体在接受过至少 3 线既往治疗(包括蛋白酶体抑制剂、免疫...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10